RTOG-0436
Terminated
Protocol Information
A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Who Are Treated Without Surgery
Principal Investigator
Mohan Suntharalingam
Status
Terminated
Date Opened To Accrual
June 30, 2008
Date Closed To Accrual
February 8, 2013
Date of Study Termination
May 20, 2022
Disease Site
Gastrointestinal [GI] Esophageal
Phase
III
Developmental Therapeutics
No
Primary Objective
To evaluate if the addition of cetuximab to paclitaxel, cisplatin, and radiation improves overall survival compared to paclitaxel, cisplatin, and radiation alone in patients with esophageal cancer who are treated without surgery
Patient Population
Histologic proof of primary squamous cell or adenocarcinoma of the esophagus or gastroesophageal junction Involvement of the GE junction with Siewert type I or II tumors Stage T1N1M0; T2-4, Any N, M0; Any T, Any N, M1a
Target Accrual
420
Protocol Documents
Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.
Patient Study Webpage
-
Share this study.
-
-
-
-
